info:eu-repo/semantics/article
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
Fecha
2012-12-12Registro en:
Neukam, Karin; Almeida, Carmen; Caruz, Antonio; Rivero Juarez, Antonio; Rallon, Norma; et al.; A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients; Oxford University Press; Journal of Antimicrobial Chemotherapy; 68; 4; 12-12-2012; 915-921
0305-7453
Autor
Neukam, Karin
Almeida, Carmen
Caruz, Antonio
Rivero Juarez, Antonio
Rallon, Norma
Di Lello, Federico Alejandro
Herrero, Rocío
Camacho, Angela
Benito, José
Macias, Juan
Rivero, Antonio
Soriano, Vicente
Pineda, Juan Antonio
Resumen
Accurate prediction of sustained virological response (SVR) to pegylated interferon-a (Peg-IFN) plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients could improve the management of these patients. We aimed to develop a model to predict SVR to Peg-IFN/ribavirin in HIV/HCV-coinfected individuals combining HCV genotype and baseline HCV RNA load with interleukin 28B and low-density lipoprotein receptor genetic variations.